The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.
 
Yara Abdou
Honoraria - Clinical Care Options; MJH Associates; WebMD/Medscape
Consulting or Advisory Role - AstraZeneca; Exact Sciences
Research Funding - Carisma Therapeutics (Inst)
Travel, Accommodations, Expenses - Carisma Therapeutics
 
Jess R Hoag
Employment - Exact Sciences
Stock and Other Ownership Interests - AstraZeneca; Exact Sciences; Lilly; Novo Nordisk; UnitedHealthcare
 
William E. Barlow
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Julie R. Gralow
No Relationships to Disclose
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Calibr; Daiichi Sankyo/Astra Zeneca; EcoR1 Capital; Eisai; Exelixis; GT Aperion; Incyte; Infinity Pharmaceuticals; Karyopharm Therapeutics; LegoChem Biosciences; Lengo Therapeutics; Menarini Group; OnCusp Therapeutics; Protai; Seagen; Tallac Therapeutics; Theratechnologies; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARTIDIS; Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Kathy S. Albain
Honoraria - Encore Medical Education
Research Funding - Quantum Leap Healthcare Collaborative (Inst); Seagen (Inst)
Other Relationship - Seagen
 
Daniel F. Hayes
Stock and Other Ownership Interests - Cellworks; InBiomotion; Xilis
Honoraria - Tempus
Consulting or Advisory Role - Artera; Arvinis; bioTheranostics; BioVica; Cellworks; Centrix; Cepheid; Epic Sciences; Exact Sciences; Freenome; Guardant Health; L-Nutra; Macrogenics; Oncocyte; Strata Oncology; Stratipath; Tempus; Turnstone Bio; xilis
Research Funding - Angle (Inst); AstraZeneca (Inst); Cepheid/Danaher (Inst); Menarini Silicon Biosystems (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Other Relationship - Cancer Expert Now; UpToDate
 
Nancy U. Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Johnson & Johnson/Janssen; Menarini; Olema Pharmaceuticals; Pfizer; Seagen
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
Travel, Accommodations, Expenses - Olema Pharmaceuticals
 
Edith A. Perez
Employment - Bolt Biotherapeutics
Leadership - Bolt Biotherapeutics
 
Lori J. Goldstein
Honoraria - AstraZeneca; Biovica; Daiichi Sankyo; Immunomedics
Consulting or Advisory Role - AstraZeneca; Biovica; Immunomedics
Research Funding - Genentech/Roche (Inst); Merck (Inst)
Other Relationship - Daiichi Sankyo
 
Stephen K. L. Chia
Honoraria - AstraZeneca; Gilead Sciences; Lilly; Merck; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst)
 
Sukhbinder K. Dhesy-Thind
Honoraria - Novartis Canada Pharmaceuticals Inc; Pfizer
Consulting or Advisory Role - Novartis Canada Pharmaceuticals Inc; Seagen
 
Priya Rastogi
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Lilly
 
Anne F. Schott
Research Funding - Arvinas (Inst); Celcuity (Inst); Genentech/Roche (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Contributor of 2 "cards" on breast cancer topics to UpToDate; Systems and Methods for Tissue Imaging, 8,185,186, Inventor, Submitted on 04/2008. This is a patent for use of diffusion MRI technology to quantitate response to neoadjuvant breast cancer therapy.
 
Jennifer M. Racz
Employment - Exact Sciences
Stock and Other Ownership Interests - Exact Sciences
Travel, Accommodations, Expenses - Exact Sciences
 
Debashish Tripathy
Consulting or Advisory Role - Ambrx; AstraZeneca; Genomic Health; Gilead Sciences; GlaxoSmithKline; Menarini; Novartis; OncoPep; Personalis; Pfizer; Roche; Sermonix Pharmaceuticals
Research Funding - Ambrx (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Novartis; Seagan
 
Lajos Pusztai
Honoraria - Athenex; bioTheranostics; natera; OncoCyte
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Bristol Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Pfizer; Roche/Genentech; Seagen; Syndax
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Foundation Medicine; NanoString Technologies
 
Priyanka Sharma
Stock and Other Ownership Interests - Amgen; Gilead Sciences (I); Johnson & Johnson/Janssen; Pfizer (I); Roche/Genentech (I); Sanofi
Consulting or Advisory Role - AstraZeneca; Boston Scientific (I); Cipla (I); Gilead Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Salient Pharmaceuticals (I); Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Kevin Kalinsky
Employment - EQRx (I); GRAIL (I)
Stock and Other Ownership Interests - EQRx (I); GRAIL (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship - Genentech; Immunomedics